Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Latest News & Features of interest to Bristol Myers Squibb
US pharma major Bristol Myers Squibb has decided to end its collaboration with Germany-based Immatics for the co-development of IMA401. 17 September 2024
Bicara Therapeutics, a biotech focused on developing bifunctional therapies for solid tumors, has closed its initial public offering, raising approximately $362 million. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
French pharma major Sanofi today revealed it is shipping Beyfortus (nirsevimab-alip) 50mg and 100mg Injection doses in the USA to private healthcare providers and to the Centers for Disease Control and Prevention. 17 September 2024
Swiss pharma giant has shared a well-timed updated analysis from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congress 2024 16 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
German pharma major Bayer today released results from the Phase III ARANOTE trial at the European Society for Medical Oncology (ESMO) taking place in Spain. 16 September 2024
Swiss pharma giant has shared a well-timed updated analysis from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congress 2024. 16 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Bristol Myers Squibb has scored a major legal victory as a judge in New York dismissed a $6.4 billion lawsuit related to its acquisition of cancer company Celgene. 1 October 2024